GI INNOVATION

SITC 2024_GI-108 POSTER

A first-in-human, open-label, multicenter, phase 1/2a, dose-escalation and expansion study of GI-108, a novel immunocytokine combining anti-CD73-IL2v, in patients with advanced or metastatic solid tumors
ASCO 2024_GI-102 POSTER

A first-in-human, phase 1/2a study of GI-102 (CD80-IL2v3) in patients with advanced or metastatic solid tumors: Initial results from dose escalation
SITC 2023_Keynote-B59 POSTER

Keynote-B59: Dose escalation of a phase 1/2 first-in-human, open-label study of GI-101, a novel immunocytokine combining CD80-IL2v, in combination with pembrolizumab in advanced solid tumors
SITC 2023_GI-102 POSTER

A first-in-human, open-label, multicenter, phase 1/2a, dose escalation and expansion study of GI-102, a novel immunocytokine combining CD80-IL2v3, in patients with advanced or metastatic solid tumors
ESMO 2023 POSTER

Population Pharmacokinetic-Pharmacodynamic Modeling to Inform Optimal Dosing Strategies for GI-101, a Novel Fusion Protein, Targeting IL2βγR and CTLA4
ESMO 2023 POSTER

An open-label, multicenter, phase 1/2 study of GI-101, CD80-IgG4 Fc-IL2v, in advanced solid tumors(Part A of GII-101-P101; KEYNOTE-B59)
SITC 2021 POSTER

A phase 1/2, open-label, dose escalation and expansion study of GI-101 as a single agent and in combination with a Pembrolizumab, Lenvatinib or Local RT in advanced solud tumors (KEYNOTE-B59)
AACR 2021 POSTER

Comprehensive preclinical study on GI-101, a novel CD80-IgG4-IL2 variant protein, as a therapeuticantibody candidate with bispecific immuno-oncology target
AACR 2020 POSTER

GI101, A novel CD80-IgG4-IL2 variant bispecific protein, inhibits tumor growth and induces anti-tumor immune response in multiple preclinical models
ESMO 2019 POSTER

GI101, a novel triple-targeting bispecific CD80-IgG4-IL2 variant fusion protein, elicits synergistic anti-tumor effects in preclinical models

COMPANY